Kornimate/medical-research-clean huggingface dataset:
micronutrient sprinkles in a daycare center

Conditions: Diarrhea; Respiratory Infection

Summary: diarrheal diseases are a major cause of morbidity and mortality globally in children less than 5 years of age. prolonged diarrhea, recurrent infections and growth failure in developing countries are usually a consequence of micronutrient deficiencies including zinc. the primary aims of the proposed study are to evaluate the effect of the use of multiple micronutrient sprinkles including zinc on compliance of supplement use and the incidence of recurrent diarrheal and respiratory illnesses. the proposed study will be conducted at the fima lifshitz metabolic research center, department of pediatrics, universidade federal da bahia, salvador-bahia, brazil over a period of 18 months. this is a double-blind placebo-controlled trial involving the use of 2 types of micronutrient sprinkles in a group of 120 children who attend a day care center in salvador, bahia. they will be randomized into 2 groups of 60 children each. the intervention group will receive sprinkles containing zinc while the control group will receive micronutrient sprinkles without zinc. the primary outcome variables of interest are zinc status, stool zinc losses and diarrhea duration. both groups of infants will be monitored at monthly intervals for an initial duration of 180 days for zinc status, diarrhea episodes, respiratory illness and growth. this study will allow for the establishment of a cohort of children who will be monitored in a micronutrient supplementation trial using sprinkles.

the proposed study will be conducted at the fima lifshitz metabolic research center, department of pediatrics, universidade federal da bahia, salvador-bahia, brazil over a period of 18 months. this is a double-blind placebo-controlled trial involving the use of 2 types of micronutrient sprinkles in a group of 120 children who attend a day care center in salvador, bahia. they will be randomized into 2 groups of 60 children each. the intervention group will receive sprinkles containing zinc while the control group will receive micronutrient sprinkles without zinc. the primary outcome variables of interest are zinc status, stool zinc losses and diarrhea duration. both groups of infants will be monitored at monthly intervals for an initial duration of 180 days for zinc status, diarrhea episodes, respiratory illness and growth. this study will allow for the establishment of a cohort of children who will be monitored in a micronutrient supplementation trial using sprinkles.

Eligibility criteria:
inclusion criteria: * healthy children attending day care exclusion criteria: * chronic medical problems including sickle cell disease, congenital heart disease

Keywords: diarrhea pneumonia upper respiratory infections acute gastroenteritis
optimizing the assessment of refractive outcomes after cataract surgery

Conditions: Cataract

Summary: the purpose of this study is to evaluate current available assessments (automated vs. manual) with which manifest refraction data and biometric variables are obtained to understand if data from an automated refractor can be utilized to optimize the a-constant as well as manual subjective refraction (ie, to a clinically insignificant difference). the a-constant is the calculated number that helps the surgeon determine which iol should be implanted in the eye during cataract surgery.

subjects will be implanted with acrysof® iq monofocal iol model sn60wf. standard clinical practice will be followed for pre-operative testing, iol power estimation and iol implantation. only one eye will be enrolled in the study per surgeon determination. the eye will undergo both an automated and manual manifest refraction assessment at 3 months postoperative.

Eligibility criteria:
inclusion criteria: * able to understand and sign an ethics committee/institutional review board approved informed consent; * willing and able to attend all scheduled study visits as required per protocol; * diagnosed with cataract in one or both eyes; * planned cataract removal by phacoemulsification with implantation of a monofocal iol; laser refractive procedures for incisions (primary and sideport), capsulorhexis and lens fragmentation are allowed; * preoperative keratometric astigmatism ≤ 1.0 diopter (d); * other protocol-defined inclusion criteria may apply. exclusion criteria: * women of childbearing potential, pregnant, or breast-feeding; * history of ocular pathology, ocular inflammation, or ocular conditions, as specified in the protocol; * previous intraocular or corneal surgery; * use of systemic medications that, in the opinion of the investigator, may confound the outcome or increase the risk of complications to the subject; * any medical condition that, in the opinion of the investigator, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject; * other protocol-defined exclusion criteria may apply.

Keywords: intraocular lens (iol)
opioid modulation and neural reward activation in healthy adults

Conditions: Alcohol Drinking; Opioid Use, Unspecified

Summary: this is a double blind study of the effects of opioid antagonism on the brain's reward response. the investigators will recruit participants to undergo two scans, one on active medication and one on placebo. during the scan, the investigators will assess reward.

the study will employ a crossover design. the study will use the monetary incentive delay task during functional mri to assess reward. this task presents participants with cues indicating whether they are playing to win $5, win $0, or to avoid losing $5. this task has been well-validated to elicit activation in a key reward response area of the brain called the ventral striatum.

Eligibility criteria:
inclusion criteria: * between 18 and 35 years of age, * is a moderate drinker (i.e. consumes 1-14 drinks/week for males, or 1-7 drinks/week for females). exclusion criteria: * non-drinker * positive result on urine drug screen or breathalyzer at the start of any study visit * inability to complete mri (e.g. presence of ferromagnetic objects in body) * current use of medications that alter the hemodynamic response such as insulin * history of trauma resulting in loss of consciousness longer than 15 minutes * currently taking opioid medications * pregnancy
clinical trial to evaluate the efficacy and safety of dwkh

Conditions: Respiratory Infection

Summary: randomized, double-blind, parellel, multicenter, active-controlled


Eligibility criteria:
inclusion criteria: * male and female aged between 19 and 80. * patients whose bss score is over 5. exclusion criteria: * patients allergic to any ingredients of the study drugs. * moderate liver disease (alt or ast \> unlx3). * moderate lung disease. * uncontrolled htn. * uncontrolled dm. * uncontrolled thyroidism. * patients who is needed antibiotics during the study period. * in the case of women, pregnant(urine-hcg positive) or lactating women.
yoga for pain and opioid dependence

Conditions: Chronic Pain; Opioid Addiction

Summary: this study is designed to develop an effective adjunctive treatment using yoga for chronic pain and opioid dependence.

this study aims to develop an adjunctive novel treatment intervention using yoga in opioid agonist maintained patients to effectively treat the co-occurring disorders of non-malignant chronic pain and opioid dependence (pod). specific aims: 1) to conduct a pre-pilot phase with 8 patients with pod receiving opioid agonist maintenance treatment.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * prescription opioid addiction or heroin addiction * moderate to severe chronic pain, * understands english exclusion criteria: * current suicide or homicide risk * life threatening or unstable medical condition * medical or psychiatric condition that is judged to be of clinical concern by the pi or admitting clinician * pregnancy

Keywords: pain addiction buprenorphine counseling methadone yoga
dna cytometry for cervical cancer screening in china

Conditions: Cervical Cancer

Summary: very few screenings of any kind will be possible during a woman's lifetime in most low-resource regions, where 80% of the half-million global cases of cervical cancer occur every year. although a single round of human papillomavirus (hpv) testing was associated with a significant decline in the rate of advanced cervical cancers and associated deaths, whether other methods like as dna image cytometry can be used as an more accurate means than others in screening cervical cancer or not is yet to be verified. in addition, the accuracy of both dna image cytometry and conventional cytology is not well known. the investigators hypothesized that dna image cytometry was superior in screening cervical cancer than conventional cytology.


Eligibility criteria:
inclusion criteria: * currently or had been married * not pregnant * had an intact uterus with no prolapse * had no history of cervical cancer * living in china exclusion criteria: * not willing to participate or finish the study at any time * history of cervical surgeries

Keywords: dna cytometry cytology diagnosis accuracy
incidence of atrial fibrillation in patients with severe obstructive sleep apnea: the reveal xt-sa study

Conditions: Obstructive Sleep Apnea; Atrial Fibrillation

Summary: single site study: the goal of the study is to determine the incidence of new onset atrial fibrillation (af) in patients with severe obstructive sleep apnea (osa) syndrome through the use of a medtronic reveal xt implantable loop recorder (ilr). the ilr device is approved for use in canada, for the assessment of atrial fibrillation.


Eligibility criteria:
inclusion criteria: 1. patients with severe osa defined as apnea hypopnea index (ahi) \> 30. 2. age \> 18 years. exclusion criteria: 1. previous history of clinical af defined as documented lone, paroxysmal, persistent or permanent, according to standard definitions. 2. patient with anticipated requirement of mri. 3. patient with well-know allergy to any component of the medtronic reveal xt. 4. patients with implantable cardiac rhythm device \[pacemakers or internal cardiac device (icds)\]. 5. women of child bearing potential. 6. unable or unwilling to provide written informed consent. 7. unable or unwilling to complete the study follow-up schedule (eg. intention to leave the kingston area over the next 3 years. 8. previously enrolled in this trial. 9. enrolled in another study that would confound the results of this trial. 10. documented history of heart failure 11. diagnosed with severe obstructive sleep apnea greater than 1 year from screening date

Keywords: sleep apnea atrial fibrillation
post-myocardial infarction remodeling prevention therapy

Conditions: Acute Myocardial Infarction; Pacing Therapy; Cardiac Remodeling; Heart Failure

Summary: the purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (mi) in patients at highest risk for adverse myocardial remodeling.


Eligibility criteria:
inclusion criteria: * myocardial infarction (mi) within the past 10 days * peak creatine phosphokinase (cpk) greater than 3000 units/litre (u/l) at time of mi, or a troponin t (tnt) greater than 10 micrograms/litre (mcg/l) * at least 18 years old * willing to comply with the protocol exclusion criteria: * documented mi greater than 10 days * chronic renal disease, as defined by estimated glomerular filtration rate (egfr) less than 30 milliliters/minute/1.73 square meter * life expectancy less than 18 months, as determined by a physician * existing pacemaker, implantable cardioverter defibrillator (icd), or cardiac resynchronization therapy (crt) device * qrs duration greater than 120 milliseconds (ms) * coronary artery bypass graft (cabg) within 30 days prior to mi, or cabg procedure planned * third degree atrioventricular (av) block or symptomatic bradyarrhythmia * persistent atrial fibrillation (af) that is not self terminating within 7 days or is terminated electrically or pharmacologically * permanent af that is non self terminating, with cardioversion failed or not attempted within the past year * new york heart association (nyha) class iv * non-ischemic cardiomyopathy * pregnant or planning to become pregnant during the study * enrolled or planning to participate in a concurrent drug and/or device study during the course of this clinical trial. co-enrollment in concurrent trials is only allowed with documented pre-approval from medtronic, documenting that there is not a concern that co-enrollment could confound the results of this trial. * breast feeding * of a vulnerable population as determined by local law or requirement, or a physician
inpatient screening mammography for non-adherent and high risk women

Conditions: Breast Cancer

Summary: the investigators propose to pilot a program that will evaluate the feasibility of an inpatient screening mammography for non-adherent and high risk hospitalized women age 52-74 admitted to the medicine services at johns hopkins bayview medical center and howard county general hospital. the two key activities include: inpatient breast care education with educational handouts and offering inpatient screening mammography. inpatient screening mammography will be offered to non-adherent (last screening mammogram more than 24 months ago) and high risk (gail 5-year risk of breast cancer 1.6 or greater) women. this pilot program will thus evaluate the feasibility of an inpatient screening mammography as an innovative approach to increase breast cancer screening among non-adherent and high risk women.


Eligibility criteria:
inclusion criteria: * women between 50 and 74 years of age who were non-adherent to breast screening guidelines exclusion criteria: * patients with a history of breast cancer or mastectomy * history of other cancers (except skin) * serious comorbidities making patient's life expectancy \<10 years

Keywords: breast cancer screening mammography
single-ascending dose study of kylo-11 in healthy subjects

Conditions: Cardiovascular Diseases

Summary: this is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. kylo-11 will be evaluated in approximately 60 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.


Eligibility criteria:
inclusion criteria: * men and women aged 18 to 55 years old, inclusive; * body mass index (bmi) between 19 kg/m2 and 30 kg/m2, inclusive; * protocol-defined elevated serum lp(a) level; * female subjects must not be able to get pregnant and male subjects must agree to adhere to contraception restrictions; * willing to comply with protocol required visits and assessments, and provide written informed consent. exclusion criteria: * history or evidence of a clinically significant disorder, condition or disease; * received an investigational drug, vaccine or device within 3 months before dosing; * history of evidence of malignant tumor or gilbert syndrome; * positive screen of hepatitis b surface antigen, hepatitis c virus, human immunodeficiency virus or syphilis infection; * history of alcohol abuse within 12 months before dosing; * history of drug abuse within 3 months before screening; * history of blood donations or blood loss of 400 ml and more within 3 months before dosing; * history of stroke or myocardial infarction within 6 months before sceening; * pregnant or breast-feeding women; * other exclusion criteria applied per protocol.
comparison of flexible & navigable suction ureteral access sheath vs. antegrade suction in retrograde flexible ureteroscopy for lower calyceal stones

Conditions: Nephrolithiasis; Urolithiasis; Endourology

Summary: this randomized controlled trial aims to compare the efficacy and safety of two suction techniques during retrograde flexible ureteroscopy (furs) for lower calyceal renal stones measuring 1.5-2 cm. the study evaluates flexible \& navigable suction ureteral access sheath (fans) versus antegrade suction (via percutaneous access) in improving stone-free rates (sfr), reducing operative time, and minimizing complications such as bleeding, ureteral injury, and infection. a total of 120 adult patients will be randomized into two groups, undergoing either flexible ureteroscopy (furs) with flexible \& navigable suction ureteral access sheath (fans) or flexible ureteroscopy (furs) with antegrade suction, at banha university faculty of medicine.


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years old) * patients diagnosed with renal stones (1.5-2 cm) confirmed by non-contrast computed tomography (ncct) * patients undergoing flexible ureteroscopy (furs) as the primary treatment approach * patients with no active urinary tract infection (uti) at baseline * patients who provide written informed consent exclusion criteria: * patients with anatomical anomalies (e.g., horseshoe kidney, puj obstruction) * patients with a single functioning kidney * pregnant women * patients with a history of urological malignancy * patients with active bleeding disorders or those on anticoagulant therapy that cannot be safely discontinued * patients at high risk for anesthesia

Keywords: flexible ureteroscopy (furs) ureteral access sheath (uas) suction ureteral access sheath (fans) antegrade suction percutaneous nephrostomy (pcn) laser lithotripsy
a study to assess the safety and efficacy of treprostinil to facilitate liver transplantation in patients with portopulmonary hypertension

Conditions: Portopulmonary Hypertension; Pulmonary Arterial Hypertension; Pulmonary Hypertension

Summary: this was a multicenter, prospective, observational, open-label study. patients meeting inclusion/exclusion criteria received treatment with treprostinil as recommended by their treating physicians and were followed according to standard of care. this observational study collected clinical data and biologic specimens from patients who were treated for portopulmonary hypertension (poph), with a goal of achieving hemodynamic parameters appropriate for orthotopic liver transplantation candidacy, including mean pulmonary arterial pressure (mpap) less than 35 mmhg and pulmonary vascular resistance (pvr) less than 3 wood-units (wu) at week 24 in patients with severe poph.

treprostinil is approved as a continuous subcutaneous (sc) or intravenous (iv) infusion by the fda for the treatment of who group i pah with new york heart association (nyha) functional class ii, iii or iv symptomatology. to date, treprostinil has not been studied in the setting of poph; however, it is commonly prescribed in this setting. this was an observational, open-label, multicenter study which documented the safety and efficacy profile of this agent in poph to facilitate orthotopic liver transplantation (olt).

Eligibility criteria:
inclusion criteria: * patients must: 1. had portal hypertension. 2. be otherwise suitable candidates for olt. 3. had severe pulmonary arterial hypertension (pah) defined as a resting mean pulmonary arterial pressure (mpap) \>35 mmhg and pulmonary vascular resistance (pvr) ≥3 wood units (wu) by right heart catheterization (rhc) performed as part of standard of care evaluation within 90 days of enrollment. 4. treprostinil therapy must be recommended by the treating physician per standard of care. 5. be nyha functional class ii, iii, or iv. 6. had pulmonary capillary wedge (pcw) pressure ≤18 mmhg and transpulmonary gradient (tpg) ≥15 mmhg. exclusion criteria: * patients must not: 1. had received any any investigational therapy as part of a clinical trial for any indication within 30 days prior to enrollment. 2. had a change in dose of treatment for pah (bosentan \[tracleer\], ambrisentan \[letairis\], tadalafil \[adcirca\], or sildenafil \[revatio\]), within 30 days prior to enrollment. that is, subjects may have been treated with any of these agents provided the dose was stable for at least 30 days prior to enrollment. 3. had renal failure requiring hemodialysis.

Keywords: pah pulmonary hypertension remodulin treprostinil quality of life
supporting self-employment in young adults with stroke

Conditions: Stroke

Summary: this project will investigate the effects of an 8-week theory-driven online/hybrid self-employment skill building intervention on the rate of self-employment, self-efficacy, life satisfaction, and psychosocial outcomes among working-age stroke survivors.

a 2-arm randomised controlled trial will be conducted. individuals aged 18-65 years old, with a first-ever/recurrent ischaemic/haemorrhagic stroke, and unemployed for at least 6 months will be recruited. eligible participants will be randomly assigned to receive usual care or a new intervention with usual care. the intervention is aimed at assisting survivors in becoming self-employed by developing entrepreneurial skills. outcomes including self-employment rate, self-efficacy, life satisfaction, emotional well-being, and community reintegration at baseline, immediately and 3 months after completing the intervention. semi-structured interviews will be conducted with participants to elicit feedback on ssi.

Eligibility criteria:
inclusion criteria: * 18-65 years old at the time of recruitment * been clinically diagnosed with a first-ever/recurrent ischaemic/haemorrhagic stroke * a montreal cognitive assessment score (moca) \>2nd percentile * a paid job (full-time/part-time) at the recent onset of stroke * been unemployed (not in paid, full-time/part-time job) for ≥6 months at the time of recruitment * able to communicate in cantonese and read traditional chinese. exclusion criteria: * diagnosed with transient ischaemic attack * cerebrovascular events due to tumour * diagnosed with a mental condition for example depression or schizophrenia * incomprehensible speech * receiving or awaiting to receive vocational programmes * self-employed at the time of recruitment or planning to retire
automated volume assessment of acute stroke

Conditions: Stroke, Software Verification, Diffusion Weighted MRI, Neuroimaging

Summary: stroke is a common disease. it is increasingly managed in non-specialized centers. the volume of the lesion, evaluated on the diffusion weighted imaging, is a prognostic factor of clinical progression and is useful for the treatment decision. there is therefore a real interest in having a reliable software able to detect the stroke and evaluate the volume of the cerebral infarction. the aim is to provide rapid information to the interventional neuroradiologist and optimize the care of the patient. the alberta stroke program early computed tomography score currently used to predict response to treatment divides the territory of the middle cerebral artery. it has a few limitations, it is unreproducible and concerns only the territory of the middle cerebral artery. manual volumetry is a long and also not very reproducible technique. the aim of our study is to evaluate the reproducibility and diagnostic performances of the automated segmentation software based on the diffusion weighted imaging sequence, and to compare it to manual and semi-automatic measurements.


Eligibility criteria:
inclusion criteria: * patients admitted for a recent neurological deficit (less than 24 hours), suspected for a stroke. non inclusion criteria : * pregnant or breastfeeding women * patients with absolute contraindications to mri